Research and Markets - Succesful Strategies behind Innovative Cancer Therapies in the Marketplace Examined

Research and Markets (researchandmarkets.com/reports/c9330) has announced the addition of Targeted Cancer Therapies: Innovative drugs and their impact on the future of oncology to their offering.

(PRWEB) November 17, 2004 -- Research and Markets (http://www.researchandmarkets.com/reports/c9330) has announced the addition of Targeted Cancer Therapies: Innovative drugs and their impact on the future of oncology to their offering.

Drugs for high-severity conditions grew over the past decade at over twice the rate of drugs for low severity conditions, traditionally served by primary care blockbuster drugs. Increasingly, pharmaceutical companies are breaking into the cancer market through brands that are launched as a therapy for a minor indication and subsequently developed for other indications and first-in-line therapies.

The new wave of innovation is being led by European companies and could bring about a revolution not only in cancer treatment, but across the industry as a whole. This report provides detailed analysis of innovation in both the diagnosis and treatment of cancer and forecasts for the success of leading drugs, enabling your company to plan effective oncology strategies.

Hot issues covered in this report:
- A review of pipeline activity shows that oncology-related products account for almost 30% of all activity. This reflects the need for innovative therapies and the high drug price levels they command due to unmet needs.
- Targeted therapies are forecast high growth rates against a backdrop of a slow growth cancer market. The ongoing success of specialized medicines will have a continued impact on the more traditional blockbuster model.
- Progress in oncogenics means an accelerated stream of novel targets for small molecule drugs, shorter timelines between discovery of new gene targets and drugs and also high throughput screening enabling quicker development.

This report can be used to:
- Analyze the key drivers of success and discover how they are moving companies away from the traditional blockbuster model.
- Identify the most succesful strategies behind innovative cancer therapies in the marketplace with case studies from Roche, Astra Zeneca and Genetentech.
- Understand the developments in oncogenics and the impact on improving the timelines of drug discovery.
- Assess the importance of new diagnostic tools and the impact of genetic counseling on treatment patterns.
- Quantify the future sales of pioneering cancer drugs the epidemiology underpinning their growth and the competitive threats facing brand leaders.

This report will provide the answers to questions, such as...
- What is the impact of declining R&D productivity on the future of cancer drug discovery?
- What advances are being made in the diagnosis of cancer?
- What are the unmet needs in cancer treatment?
- What new treatments are being developed in areas such as breast cancer, colorectal cancer and prostate cancer?
- Who are the key players and what lessons do they provide about the future of targeted cancer therapies?
- What are the sales forecasts for key brands such as Tarceva and Eloxatin?
- How will targeted therapies help change the structure of the pharmaceutical industry?

Contents of this report include:
- Beyond the blockbuster model
- Emerging therapies
-Therapy area analysis

-Case studies
Sanofi-Aventis
Sanofi-Synthélabo
Eloxatin
Aventis: development of oncology as a blockbuster franchise
Aventis cancer portfolio and R&D pipeline
Taxotere
Roche
Tarceva
Genentech
Avastin
AstraZeneca
Iressa

- Conclusions
Challenges for development of targeted cancer therapies
Diagnostics are integral to targeted therapies
European companies will dominate targeted cancer therapies
The future of oncology
Beyond targeted medicines

For more information visit http://www.researchandmarkets.com/reports/c9330

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 98

###